These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36567199)

  • 61. The role of phosphorylation in synucleinopathies: focus on Parkinson's disease.
    Cavallarin N; Vicario M; Negro A
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):471-81. PubMed ID: 20522010
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synucleins Have Multiple Effects on Presynaptic Architecture.
    Vargas KJ; Schrod N; Davis T; Fernandez-Busnadiego R; Taguchi YV; Laugks U; Lucic V; Chandra SS
    Cell Rep; 2017 Jan; 18(1):161-173. PubMed ID: 28052246
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neural activity controls the synaptic accumulation of alpha-synuclein.
    Fortin DL; Nemani VM; Voglmaier SM; Anthony MD; Ryan TA; Edwards RH
    J Neurosci; 2005 Nov; 25(47):10913-21. PubMed ID: 16306404
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles.
    Lee SJ; Jeon H; Kandror KV
    Acta Neurobiol Exp (Wars); 2008; 68(4):509-15. PubMed ID: 19112474
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein.
    Sarafian TA; Littlejohn K; Yuan S; Fernandez C; Cilluffo M; Koo BK; Whitelegge JP; Watson JB
    J Neurosci Res; 2017 Sep; 95(9):1871-1887. PubMed ID: 28117497
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
    Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
    Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structural basis of synaptic vesicle assembly promoted by α-synuclein.
    Fusco G; Pape T; Stephens AD; Mahou P; Costa AR; Kaminski CF; Kaminski Schierle GS; Vendruscolo M; Veglia G; Dobson CM; De Simone A
    Nat Commun; 2016 Sep; 7():12563. PubMed ID: 27640673
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aquaporin-4 and Parkinson's Disease.
    Lapshina KV; Ekimova IV
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338949
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts.
    Strohäker T; Jung BC; Liou SH; Fernandez CO; Riedel D; Becker S; Halliday GM; Bennati M; Kim WS; Lee SJ; Zweckstetter M
    Nat Commun; 2019 Dec; 10(1):5535. PubMed ID: 31797870
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fatal attraction - The role of hypoxia when alpha-synuclein gets intimate with mitochondria.
    Burtscher J; Syed MMK; Keller MA; Lashuel HA; Millet GP
    Neurobiol Aging; 2021 Nov; 107():128-141. PubMed ID: 34428721
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Amyloid oligomerization of the Parkinson's disease related protein α-synuclein impacts on its curvature-membrane sensitivity.
    Gallea JI; Ambroggio EE; Vilcaes AA; James NG; Jameson DM; Celej MS
    J Neurochem; 2018 Nov; 147(4):541-556. PubMed ID: 30142705
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.
    Calabresi P; Mechelli A; Natale G; Volpicelli-Daley L; Di Lazzaro G; Ghiglieri V
    Cell Death Dis; 2023 Mar; 14(3):176. PubMed ID: 36859484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Alpha-synucleinopathy reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD+ pathway.
    Parsons RB; Kocinaj A; Ruiz Pulido G; Prendergast SA; Parsons AE; Facey PD; Hirth F
    Hum Mol Genet; 2022 Aug; 31(17):2918-2933. PubMed ID: 35397003
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 77. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.
    Garcia-Reitböck P; Anichtchik O; Bellucci A; Iovino M; Ballini C; Fineberg E; Ghetti B; Della Corte L; Spano P; Tofaris GK; Goedert M; Spillantini MG
    Brain; 2010 Jul; 133(Pt 7):2032-44. PubMed ID: 20534649
    [TBL] [Abstract][Full Text] [Related]  

  • 78. α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin.
    Maor G; Dubreuil RR; Feany MB
    J Neurosci; 2023 Mar; 43(9):1614-1626. PubMed ID: 36653193
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α-synuclein.
    Lang A; Dassler E; Milenkovic I; Lutz MI; Kovacs GG
    Parkinsonism Relat Disord; 2021 Sep; 90():57-61. PubMed ID: 34385008
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies.
    Kawahata I; Finkelstein DI; Fukunaga K
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.